The rising frequency of kidney-related illnesses is projected to propel the tissue engineering industry forward. With an ageing population and an increase in chronic illnesses, there is a need for more effective medical treatments, and therefore a demand for qualified tissue engineering researchers, which is likely to fuel market expansion throughout the forecast period. Tissue engineering methods currently available face several challenges, including ineffective cell growth, insufficient and unstable production of growth factors to stimulate cell communication and proper response, and a lack of appropriate biomaterials and techniques to capture appropriate physiological architectures. Another restriction of tissue engineering is the inability to manage cellular processes and their varied characteristics (biological, mechanical, electrochemical, and others), as well as challenges with biomolecular detection and biosensors. Additionally, despite increased interest in tissue engineering research, advances and the high cost of therapy are impeding market expansion.
According to Coherent Market Insights, Global Tissue Engineering Market is estimated to be valued at US$ 9,436.0 million in 2022 and is expected to exhibit a CAGR of 11.7% during the forecast period (2022-2030).
Market Players in the Tissue Engineering Industry:
1. Allergan Plc.
The company is Operator of a pharmaceutical company intended to focus on manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products. The company engages in medical aesthetics, eye care, central nervous system and gastroenterology and delivers innovative patient care, enabling its customers to avail the solution for enhanced availability of medicinal products to cure several diseases in the market. The company was founded in 1983, headquartered in Dublin, Ireland.
2. Athersys, Inc.
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
3. B. Braun
B. Braun Medical is a medical device manufacturing company that specializes in infusion therapy and pain management. Braun Medical was founded in 1839 and headquartered in Bethlehem, Pennsylvania.
4. BioMimetic Therapeutics
BioMimetic Therapeutics was founded on 1999 and is headquartered in Franklin, Tennessee. BioMimetic Therapeutics is a biotechnology company that develops products to help stimulate the body natural tissue regenerative process. The company's products and product candidates include Augment Injectable and Augment Rotator Cuff for several orthopedic and sports medicine indications comprising the treatment of foot and ankle fusions, the stimulation of wrist fracture healing, and the surgical treatment of rotator cuff tears, as well as Augment Tendinopathy Injection for injuries cause of tendon overuse. In Mar 12, 2019 Wright Medical closes rights agreement for BioMimetics buyout
5. Bio Tissue Technologies
The company is Provider of ortho-biological devices for cartilage defects for patients and health professionals. The company offers a three dimensional autologous chondrocyte graft to treat articular cartilage defects in the knee. The company was founded in 1997, headquartered in Geneva, Switzerland.
6. International Stem Cell
International Stem Cell Corporation (ISCO) is a publicly traded biotechnology company with a powerful new stem cell technology called parthenogenesis which uses unfertilized eggs, and promises to significantly advance the field of regenerative medicine by addressing the problem of immune-rejection. The company was founded in 2001, headquartered in California, U.S.
7. Medtronic, Inc.
Medtronic provides healthcare technology solutions for complex and challenging conditions. They deliver treatments and therapies for the lungs, brain, dental, diabetes, ENT, heart, gastrointestinal, orthopedic, urinary, and women's health. The company was founded in 1949, headquartered in MInnesotta, U.S.
8. Organogenesis Inc.
Organogenesis Inc. is a regenerative medicine company with the unique skill set to take complex, living therapies from research and development (R&D), through manufacturing. Organogenesis received the first FDA approval of a living, allogeneic, cell based product (Apligraf®, approved for the treatment of venous leg ulcers). Apligraf is now the leading regenerative medicine product in the world, with two FDA-approved indications. The company was founded in 1985, headquartered in Canton, U.S. In April 2022, Organogenesis Inc, announced that the latest advanced wound care research on its PuraPly AM, Affinity, Apligraf, NuShield, Novachor, and Organogenesis Physician Solutions product lines would be showcased at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference, held between April 6 and April 10, 2022, in Phoenix, Arizona.
*Definition- Tissue engineering is an interdisciplinary discipline concerned with the development of functional three-dimensional tissues using cells, scaffolds, and bioactive chemicals.
